Literature DB >> 19373885

Myasthenia gravis associated with etanercept therapy.

Dominic B Fee1, Edward J Kasarskis.   

Abstract

Etanercept is an antagonist of tumor necrosis factor alpha that was developed to treat rheumatoid arthritis. In this report we present a patient who developed myasthenia gravis while taking etanercept and had resolution of symptoms after stopping it. This is the first report of this potential side effect and is of additional interest, because etanercept has been proposed as a treatment for myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19373885     DOI: 10.1002/mus.21280

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  12 in total

Review 1.  Adalimumab-induced myasthenia gravis: case-based review.

Authors:  Eleftherios Pelechas; Tereza Memi; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2020-04-22       Impact factor: 2.631

Review 2.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 3.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 4.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 5.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 6.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

7.  Treatment of myasthenia gravis based on its immunopathogenesis.

Authors:  Jee Young Kim; Kee Duk Park; David P Richman
Journal:  J Clin Neurol       Date:  2011-12-29       Impact factor: 3.077

Review 8.  New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review.

Authors:  Tsubasa Takizawa; Marenori Kojima; Shigeaki Suzuki; Takashi Osada; Satoshi Kitagawa; Jin Nakahara; Shinichi Takahashi; Norihiro Suzuki
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

9.  Identification of the Regulatory Role of lncRNA SNHG16 in Myasthenia Gravis by Constructing a Competing Endogenous RNA Network.

Authors:  Jianjian Wang; Yuze Cao; Xiaoyu Lu; Xiaolong Wang; Xiaotong Kong; Chunrui Bo; Shuang Li; Ming Bai; Yang Jiao; Hongyu Gao; Xiuhua Yao; Shangwei Ning; Lihua Wang; Huixue Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-18       Impact factor: 8.886

Review 10.  New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.

Authors:  Ruksana Huda
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.